Figure 2. Prox1-creER^T2 is active in LECs but not other LNSCs or haematopoietically derived cells.

Prox1-CreER^T2 x EYFP^stop-flox (Prox1xEYFP) mice were maintained on tamoxifen chow for 2 weeks. Pooled inguinal, axillary and brachial LNs from B6 or Prox1xEYFP mice were enzymatically digested and EYFP expression in LECs (DAPI^negCD45^negCD31⁺gp38⁺), BECs (DAPI^negCD45^negCD31⁺gp38^neg), FRCs (DAPI^negCD45^negCD31^neggp38⁺), DCs (DAPI^negCD11c^high), macrophages (DAPI^negCD11c^neg/lowCD11b⁺), B cells (DAPI^negCD19⁺), CD4 T cells (DAPI^negCD4⁺CD19^neg) and CD8 T cells (DAPI^negCD8⁺ CD19^neg) was analysed by flow cytometry. Numbers refer to the percent of EYFP⁺ cells in the Prox1xEYFP mice. Data representative of two independent experiments with 1–2 mice each.